What is NAD+ IV therapy?

NAD+ IV therapy is an appointment rather than a product: what you buy is chair time, a nurse and an infusion, billed by the occasion instead of by the month. It is the one NAD+ route with published human studies behind it, and what those studies measured is mostly how long a session runs and how it felt — not whether it works.

What a session is, in sellers’ own words

Only 2 of 107 sellers on this roster publish an IV figure, and that is a fact about the roster before it is a fact about the market. It was built by reading companies that ship a product to a home address; a clinic chair is a different business and mostly a local one, so the IV is under-represented here by construction rather than by judgment. What the 6 figures behind those 2 sellers do establish is the shape of the purchase, and on that they agree.

The unit is the session, and the sellers say so in their own words. Every distinct phrase printed beside an IV figure on this roster:

• “1 session”
• “3 sessions”
• “Concierge home session”
• “per infusion”

Not one of them is a month, and one of them is not even a clinic: a seller here prices a session at your address. What they share is the unit, and that is the whole difference between a drip and the injection. A drip is an occasion you buy, and a vial and syringes are a subscription you enter. Neither seller here publishes how long a session lasts, which is the first thing a reader would want from a product priced by the occasion.

How it is billed

Two ways, and both of them are per-occasion. Of the 6 figures here, 4 are a single session bought on its own and 2 are a block of sessions paid for up front. Not one is a standing monthly rate. Half of them, 3 of 6, state the milligrams the session delivers, which leaves 3 putting a price on an amount the page never names.

The prepaid block is the one worth slowing down on, because it is where a per-session figure quietly turns into a commitment. A package is not a discount until you have been to the first appointment, and dividing its total by the number of sessions produces a per-session number nobody is actually charged unless they finish the block. This site does not print that division anywhere, for that reason.

Setting an IV figure against a monthly subscription is a separate problem, and it has its own page: why a per-session price is not a cheaper price walks through what you need from both sellers before the two numbers mean anything next to each other.

Computed from 2 sellers’ own pages, read September 2026. One row per distinct figure, so a seller publishing three prices is counted three times.

What has been measured in people

This is the only NAD+ route with human studies behind it, and there are two. A PubMed title search for NAD+ with intravenous or infusion returns 8 records; two of them were done in people and the rest are preclinical or about a different molecule.

PubMed, searched September 2026. The query ("NAD+"[Title] OR "NAD"[Title] OR "nicotinamide adenine dinucleotide"[Title]) AND ("intravenous"[Title] OR "infusion"[Title]) returned 8 records. Every hit was opened. Two are studies in people and both are captured here (pmid 31572171 and 41704678). The rest are preclinical or about a different molecule: a preclinical drug profile, intravenous NR in mice, rat renal hemodynamics, angiotensin II in vitro, and two papers from the 1970s. A count is what one search returned on one day, not proof that nothing exists anywhere.

What happens to the molecule

A 2019 pilot study followed plasma and urine through a six-hour infusion. Circulating NAD+ and its metabolites did not change for the first two hours, the compound was cleared from plasma across that window, and it turned up in urine by six hours. Its own abstract states that no data on the fate of directly infused NAD+ in people existed before it. Grant R and 6 others, A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD. Front Aging Neurosci, 2019. PubMed 31572171.

What the appointment was like

A 2026 retrospective review compared people given NAD+ by IV with people given nicotinamide riboside by IV at a commercial clinic, over four consecutive days with thirty days of follow-up. The NAD+ group reported moderate to severe gastrointestinal symptoms, a raised heart rate and chest pressure during infusions; all of it resolved when the infusion finished, and the symptoms stretched sessions out to an average of 97 minutes against 37 for the other group. Liver enzymes, hsCRP, kidney markers and TSH did not move over the thirty days. Reyna K and 6 others, Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Front Aging, 2026. PubMed 41704678.

Read those two together and the useful shape of the evidence appears. Something measurable happens: the molecule goes somewhere, and the experience is distinctive enough to more than double the length of an appointment. What neither study is, is a test of whether an NAD+ IV makes anyone better at anything. The second one says as much in its own conclusion, calling its results preliminary and asking for work on effectiveness beyond thirty days.

So a clinic quoting you for a session is quoting you for a procedure whose short-term tolerability has been described once, in a retrospective review, and whose benefits have not been established in a trial. Whether any of it is appropriate for you is a question for a licensed clinician who knows your history, and it is the one question in all of this with no commercial answer.

What to ask a clinic

• How long the appointment is scheduled for. Neither seller on this roster publishes it, and the one study that timed it found the NAD+ group averaging well over an hour and a half.
• Milligrams per session, as a number. Of the 6 figures here, 3 do not say, and without it one clinic’s session price cannot be compared with another’s.
• Whether the price is one session or a block. A package total is the number you commit to, not the number you pay per visit.
• What happens if you stop mid-block. Ask before you buy the block, not after.
• Who is in the room, and what they do if you feel unwell. The published account of tolerability is the reason this question is not a formality.
• Whether anything else is in the bag. A drip billed as NAD+ is sometimes a mix, and a mixed bag is a different purchase from the one you priced.

If a clinic answers those six, you can compare it with another clinic. If it answers none of them, you are being asked to pay per occasion for an occasion nobody has described. That is the same problem the board keeps turning up at the other end of the price range.

Every figure above is a seller’s own published number, with the route it buys, the milligrams it buys and the date it was read attached. None of it is medical advice, and nothing here is a recommendation to take or avoid anything. Talk to a licensed clinician who has your history in front of them.

The other 18

• NAD+ injection side effects

  Which questions are worth asking depends on the route, and on whether the seller states a dose at all.

• NAD+ IV vs injection

  A per-session price and a per-month price are not comparable until you have the milligrams for both.

• How often you take NAD+

  Frequency is usually a billing cadence before it is a clinical one. Here is how to tell which you are looking at.

• What NAD+ injections are

  A vial and syringes on a subscription, not a clinic drip. What sellers charge for one, how few state the milligrams, and what has been measured in people.

• Do NAD+ patches work

  No published study has measured NAD+ getting through human skin from a patch. What is sold anyway, and the search that says so.

• The nine routes

  NAD+ is sold nine ways, and a third of the sellers name none of them. Every route, how many sellers use each, and how large the silent group is.

• “Route not stated”

  The second largest group on the roster is the sellers who did not say. Some wrote nothing; others wrote a sentence that still is not a route. Every one of those sentences.

• Sublingual NAD+ and precursors

  Two different molecules are sold under one word. On 18 of 26 sellers it took a second look at the page to tell which one was on sale.

• What a NAD+ price includes

  Most figures never say what is in the number, and whether a seller tells you depends on the route. What this roster can say, and the one thing it cannot.

• NAD+ price by route

  Is the spray cheaper than the injection? Fifteen sellers price both, and they do not agree with each other.

• Sellers that sell NAD+ more than one way

  A brand offering NAD+ two ways is offering two purchases at two prices. How many do, which routes travel together, and how many never say.

• Who states the milligrams

  A price without a dose is not comparable. The nasal sellers state milligrams more often than the injection sellers do, and the routeless figures state them least.

• How a route is billed

  Not one figure for the two routes that need a clinic is a standing monthly rate. Sublingual is the weekly route. What kind of number each route publishes.

• When the URL names a route

  A seller's own address is the first route claim a buyer meets. “Nasal” meant nasal every time. “Oral” never once meant the precursor a reader would expect.

• Pages that publish no price

  The most common outcome of opening a NAD+ product page is not a number. What the silent ones did instead, and the one signal that predicted them in advance.

• Prices in the markup

  Most NAD+ pages carry dollar amounts you are not shown. Why that is a reason to open the toggles rather than an accusation.

• The price behind the intake

  “They don’t publish a price” is only honest if you clicked the button. Thirty-three sellers were followed one click past the page. Almost none of it was a price.

• Pages that price two routes

  Where a spray and a needle are sold in one grid, a route choice looks like a price choice. Which routes get sold side by side, and how deep it goes.